<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03409757</url>
  </required_header>
  <id_info>
    <org_study_id>16-058</org_study_id>
    <nct_id>NCT03409757</nct_id>
  </id_info>
  <brief_title>Velphoro and Impact on the Oral Cavity and Gut Microbiome</brief_title>
  <acronym>MicrobiomEisen</acronym>
  <official_title>Velphoro and Impact on the Oral Cavity and Gut Microbiome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RWTH Aachen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RWTH Aachen University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study will be carried out to determine if the regular intake of iron-based&#xD;
      Velphoro® by hyperphosphatemia patients influences the microbiome in the oral cavity and/or&#xD;
      the gut.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this study is to investigate potential changes in the microbiome of the oral&#xD;
      cavity and/or gut in patients with hyperphosphatemia following Velphoro® intake for one&#xD;
      month. The principal intention of this study is to assess consequences of Velphoro®&#xD;
      medication beyond phosphate control. Adherence to the drug might be compromised by e.g.&#xD;
      staining of teeth and biofilm after chewing the product more than recommended. Most likely&#xD;
      this is a cosmetic problem only and easy to solve by optimizing oral hygiene. The increased&#xD;
      level of iron may have an effect on the gut microbiome which could lead to mild diarrhoea.&#xD;
      However, the present study will assess, whether the microbiome both oral and gut changes&#xD;
      significantly due to some iron bio-availability, although this is expected to be low with&#xD;
      sucroferric oxyhydroxide.&#xD;
&#xD;
      The ultimate goal is to improve patient adherence to the drug and to resolve potential safety&#xD;
      concerns.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Insufficient Patient Recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">February 28, 2018</start_date>
  <completion_date type="Actual">October 6, 2020</completion_date>
  <primary_completion_date type="Actual">October 6, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>change in relative abundances of iron depending bacterial species within the microbiome from before Velphoro medication to afterwards</measure>
    <time_frame>4 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of distribution of bacterial species within the microbiome from baseline to after Velphoro medication</measure>
    <time_frame>4 weeks</time_frame>
    <description>via diversity measure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">22</enrollment>
  <condition>Hyperphosphatemia</condition>
  <arm_group>
    <arm_group_label>hemodialysis patients with hyperphosphatemia</arm_group_label>
    <description>dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool&#xD;
Velphoro® medication</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>- dental investigation and two sample collections of saliva, gingival biofilm (plaque) and stool</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velphoro</intervention_name>
    <description>4 weeks</description>
    <arm_group_label>hemodialysis patients with hyperphosphatemia</arm_group_label>
    <other_name>Sucroferric oxyhydroxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>saliva collection</intervention_name>
    <description>2 samples</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>hemodialysis patients with hyperphosphatemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Supragingival biofilm collection</intervention_name>
    <description>2 samples</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>hemodialysis patients with hyperphosphatemia</arm_group_label>
    <other_name>plaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>stool collection</intervention_name>
    <description>2 samples</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>hemodialysis patients with hyperphosphatemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood collection</intervention_name>
    <description>2 samples</description>
    <arm_group_label>hemodialysis patients with hyperphosphatemia</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      gingival biofilm, saliva and stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        hemodialysis patients suffering from hyperphosphatemia and healthy volunteers from the&#xD;
        clinical routine in the Department of Operative Dentistry, Periodontology and Preventive&#xD;
        Dentistry at the university hospital RWTH Aachen&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Suffering from hyperphosphatemia&#xD;
&#xD;
          -  Current treatment with a stable dose of a non-iron containing phosphate binder,&#xD;
&#xD;
          -  No or only parenteral iron application&#xD;
&#xD;
          -  Age of ≥ 18 years&#xD;
&#xD;
          -  Written informed consent prior to study participation&#xD;
&#xD;
          -  The subject is willing and able to follow the procedures outlined in the protocol&#xD;
&#xD;
        Control group:&#xD;
&#xD;
          -  Normal renal function&#xD;
&#xD;
          -  No hyperphosphatemia&#xD;
&#xD;
          -  Age- and sex-matched and oral disease status-matched (dental caries and periodontal&#xD;
             disease) in comparison to the hyperphosphatemia group&#xD;
&#xD;
          -  Written informed consent prior to study participation&#xD;
&#xD;
          -  The subject is willing and able to follow the procedures outlined in the protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age less than 18 years&#xD;
&#xD;
          -  Currently on oral iron application&#xD;
&#xD;
          -  Antibiotic treatment within the last two months&#xD;
&#xD;
          -  Severe medical events within the last three months&#xD;
&#xD;
          -  Planned surgery for the duration of the sampling&#xD;
&#xD;
          -  Acute/chronic gastrointestinal infections&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Oral candidiasis&#xD;
&#xD;
          -  Oral cancer&#xD;
&#xD;
          -  Pregnant and lactating females&#xD;
&#xD;
          -  Haemochromatosis history&#xD;
&#xD;
          -  Committed to an institution by legal or regulatory order&#xD;
&#xD;
          -  Participation in a parallel interventional clinical trial&#xD;
&#xD;
          -  Receipt of an investigational drug within 30 days prior to inclusion into this study&#xD;
&#xD;
          -  The subject is mentally or legally incapacitated&#xD;
&#xD;
        Only for the patient group:&#xD;
&#xD;
          -  Never got any phosphate binder&#xD;
&#xD;
          -  Allergy to Velphoro®&#xD;
&#xD;
          -  Celiac disease or any other chronic inflammatory bowel disease&#xD;
&#xD;
          -  Previous major surgery in the gastrointestinal tract&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospital of RWTH Aachen, Department of Medicine II</name>
      <address>
        <city>Aachen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 24, 2018</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 25, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperphosphatemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

